Lynda C. Schneider
A5074630013- Food Allergy and Anaphylaxis Research
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Immunodeficiency and Autoimmune Disorders
- Respiratory and Cough-Related Research
- Drug-Induced Adverse Reactions
- Immune Cell Function and Interaction
- Transgenic Plants and Applications
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- T-cell and B-cell Immunology
- NF-κB Signaling Pathways
- Food Safety and Hygiene
- Pediatric health and respiratory diseases
- Blood disorders and treatments
- IL-33, ST2, and ILC Pathways
- Inhalation and Respiratory Drug Delivery
- Hemophilia Treatment and Research
- Mast cells and histamine
- Autoimmune Bullous Skin Diseases
- Pancreatic function and diabetes
- Viral gastroenteritis research and epidemiology
Boston Children's Hospital
2016-2025
Harvard University
2016-2025
Robert Koch Institute
2025
European Centre for Disease Prevention and Control
2025
Walsh University
2024
Boston Children's Museum
2013-2024
Swiss Red Cross
2023
University College London
2021
The George Institute for Global Health
2021
RELX Group (United States)
2020
Peanut-induced anaphylaxis is an IgE-mediated condition that estimated to affect 1.5 million people and cause 50 100 deaths per year in the United States. TNX-901 a humanized IgG1 monoclonal antibody against IgE recognizes masks epitope CH3 region of responsible for binding high-affinity Fcε receptor on mast cells basophils.
Rating scales for assessing the mentally ill usually focus on role functioning of clients and their psychiatric symptomatology. This article introduces a rating scale to measure more directly observable behavioral daily living skills in mental hospitals community. Results are presented from series studies designed test instrument's psychometric properties.
There are currently no approved treatments for peanut allergy.To assess the efficacy and adverse events of epicutaneous immunotherapy with a patch among peanut-allergic children.Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, August 18, 2017. Participants included children (aged 4-11 years [n = 356] without history severe anaphylactic reaction) developing objective symptoms during food challenge an eliciting dose 300...
<h3>Importance</h3> Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. <h3>Objective</h3> To determine the optimal dose, adverse events (AEs), efficacy of a patch treatment. <h3>Design, Setting, Participants</h3> Phase 2b double-blind, placebo-controlled, dose-ranging trial peanut-allergic patients (6-55 years) from 22 centers, with 2-year, open-label extension (July 31, 2012-July 2014; completed...
No approved treatment for peanut allergy exists children younger than 4 years of age, and the efficacy safety epicutaneous immunotherapy with a patch in toddlers are unknown. We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving 1 to 3 age confirmed by food challenge. Patients who had an eliciting dose (the necessary elicit allergic reaction) 300 mg or less protein were assigned 2:1 ratio receive delivered means (intervention group) placebo...
Atopic dermatitis (AD) is an inflammatory skin condition with multiple systemic treatments and uncertainty regarding their comparative impact on AD outcomes.